Mohammad Shafi Kuchay
Mohammad Shafi Kuchay is an expert in Endocrinology at Medanta The Medicity (India). As of October 2026, ScienceLeadR ranks Mohammad Shafi Kuchay in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders, and in the top 1% of experts in India for MASH. Mohammad Shafi Kuchay has authored 75 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 3 of them ongoing. SLR score: 415 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Hepatology - Gastroenterology - Nutrition
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 75
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| MASLD as a crucial component in the pathogenesis, evaluation and management of type 2 diabetes in Asian Indians. PMID 42225043 — diabetes mellitus, diabetes mellitus, type 2 | Diabetes Metab Syndr | 2026 | 0 |
| Composite dietary antioxidant index and risk of metabolic dysfunction - associated steatotic liver disease: evidence from a prospective cohort study. PMID 42163371 — liver diseases, stress, physiological, cohort studies, liver, antioxidants, risk factors | Nutr Metab (Lond) | 2026 | 0 |
| Challenges in the Diagnosis and Management of a Paediatric Patient With Normotensive Pseudohypoaldosteronism Type IID. PMID 42057493 — kidney diseases, genes, hyperkalemia, aldosterone, renin, diagnosis, hypotension, therapeutics, pseudohypoaldosteronism, mutation, thiazides, acidosis | Nephrology (Carlton) | 2026 | 0 |
| Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes fasting during Ramadan: A meta-analysis. PMID 41696110 — diabetes mellitus, sodium-glucose transport proteins, fasting, safety, drug-related side effects and adverse reactions, hypotension, orthostatic, hypotension, hypoglycemia, dizziness, diabetes mellitus, type 2 | World J Diabetes | 2026 | 0 |
| Performance of fibrosis-4 and NAFLD fibrosis score for screening liver fibrosis in Indian individuals with type 2 diabetes: a prospective cross-sectional study. PMID 41637800 — diabetes mellitus, cross-sectional studies, fibrosis, non-alcoholic fatty liver disease, liver, diabetes mellitus, type 2 | Diabetes Metab Syndr | 2026 | 1 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus NCT06060392 — liver diseases, diabetes mellitus, liver transplantation, non-alcoholic fatty liver disease, body composition, liver, obesity, transplants, therapeutics, fatty liver, transplantation, diabetes mellitus, type 2, semaglutide | N/A | Recruiting | 2023 |
| Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes Renal Outcomes Body Composition in Renal Transplant Recipients With Diabetes Mellitus NCT06095492 — diabetes mellitus, sodium-glucose transporter 2 inhibitors, safety, insulin, body composition, hyperglycemia, kidney, transplants, therapeutics, hypoglycemic agents, kidney transplantation, steroids, transplantation, linagliptin, diabetes mellitus, type 2 | N/A | Recruiting | 2023 |
| Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes NCT06035874 — liver diseases, diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemias, liver, alcoholics, fatty liver, fatty liver, alcoholic, diabetes mellitus, type 2 | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map